Bioverativ Inc. (BIVV) announced Monday morning that it has agreed to be acquired by Sanofi for $105 per share in cash, approximately $11.6 billion.
Bioverativ gapped open dramatically higher Monday, but moved in a narrow range throughout the session. The stock closed up by 39.68 at $103.79 on the highest volume of the year. Bioverativ soared to a new high for the year.
For comments and feedback contact: editorial@rttnews.com
Business News